

Title: Alzheimer's disease neuropathologic change mediates the relationship between ambient air pollution and dementia severity

Authors: Boram Kim, M.D.¹, Kaitlin Blam¹, Holly Elser, M.D., Ph.D.², Sharon X. Xie, Ph.D.³, Vivianna M. Van Deerlin, M.D., Ph.D.⁴, Trevor M. Penning, Ph.D.⁵, Daniel Weintraub, M.D.⁶, David J. Irwin, M.D.², Lauren M. Massimo, Ph.D., CRNP², Corey T. McMillan, Ph.D.², Dawn Mechanic-Hamilton, Ph.D.², David A. Wolk, M.D.², Edward B. Lee, M.D., Ph.D.^{1,4*}

Author affiliations:

¹ Translational Neuropathology Research Laboratory, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA

² Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA

³ Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA

⁴ Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA

⁵ Center of Excellence in Environmental Toxicology, Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA

⁶ Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA

* Corresponding Author: Edward B. Lee, MD, PhD

Director, Center for Neurodegenerative Disease Research Brain Bank

Co-Director, Institute of Aging

Associate Director, Penn Alzheimer's Disease Research Center

Associate Professor of Pathology and Laboratory Medicine

Perelman School of Medicine at the University of Pennsylvania

613A Stellar Chance Laboratories

422 Curie Blvd

Philadelphia, PA 19104, USA

E-mail: edward.lee@penntmedicine.upenn.edu

Word count: 2687

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Background: Exposure to fine particulate matter air pollution (PM_{2.5} increases risk for dementia. However, it is unknown whether this relationship is mediated by dementia-related neuropathologic change found at autopsy. We aimed to examine relationships between PM_{2.5} exposure, dementia severity, and dementia-associated neuropathologic change.

Methods: This cross-sectional study used harmonized demographic, clinical, genetic, and neuropathological data from autopsy cases collected from 1998 to 2022 at the Center for Neurodegenerative Disease Research brain bank, University of Pennsylvania. Cases who had common neuropathologic forms of dementia and complete data on neuropathologic measures, *APOE* genotype, and residential address were included in this study cohort. Dementia severity was measured by Clinical Dementia Rating-Sum of Boxes (CDR-SB) scores. Ten dementia-associated neuropathologic measures representing Alzheimer's disease, Lewy body disease, limbic-predominant age related TDP-encephalopathy, and cerebrovascular disease were graded or staged according to the consensus criteria. One-year average PM_{2.5} exposure prior to death was estimated using a spatiotemporal prediction model based on residential addresses as the primary exposure measure. Linear, logistic and structural equation models were used to examine the relationships between PM_{2.5}, CDR-SB and neuropathologic measures.

Results: A total of 861 autopsy cases were included (mean age at death 76.6 years [SD 10.3]; 481 [56%] male). Each 1 µg/m³ increase in one-year average PM_{2.5} concentration prior to death was associated with significantly greater cognitive and functional impairment (increase in CDR-SB score of 0.78; 95% confidence interval [CI], 0.52-1.05), faster cognitive and functional decline (change in CDR-SB scores of 0.13; 95% CI, 0.09-0.16), more severe

Alzheimer's disease neuropathologic change (ADNC; odds ratio [OR] of 1.07; 95% CI, 1.01-1.13), and a higher prevalence of large infarcts (OR, 1.17; 95% CI, 1.05-1.30). The relationship between PM_{2.5} exposure and CDR-SB was mediated by ADNC (change in CDR-SB score due to ADNC level of 0.36; 95% CI, 0.13-0.65).

Conclusions: PM_{2.5} exposure may increase dementia risk by increasing ADNC. Measures that improve air quality may represent a population-level intervention for the prevention of dementia.

Introduction

Air pollution is a risk factor for dementia.¹ Studies consistently show that exposure to air pollution, or more specifically fine particulate matter with aerodynamic diameter less than 2.5µm (PM_{2.5}), is associated with an increased incidence of dementia,² impaired cognitive function,^{3,4} and accelerated cognitive decline.⁵ Disease-modifying therapies that target the underlying neuropathology of Alzheimer's disease (AD) show partial clinical benefit, but substantial economic and logistical barriers preclude widespread implementation and serious side effects occur in some instances.^{6,7} Efforts to curb PM_{2.5} levels has the potential to benefit health outcomes and prevent dementia risk at the population level.

Despite growing evidence of the adverse effect of PM_{2.5} on cognition,^{8,9} the underlying biological mechanisms for this relationship are largely unknown. PM_{2.5} exposure has been associated with brain volume loss,¹⁰ cortical atrophy,^{11,12} lower cerebrospinal fluid amyloid-β₄₂ levels¹³, increased amyloid PET positivity,¹⁴ and accelerated epigenic aging,¹⁵ raising the possibility that PM_{2.5} might contribute to dementia risk by enhancing Alzheimer's disease neurodegenerative disease pathways.^{16,17} Post-mortem autopsy examination remains the gold standard for the neuropathologic diagnosis of Alzheimer's disease and related dementias. However, few post-mortem studies have investigated the association between PM_{2.5} and neurodegenerative disease pathology^{18,19}, and the tripartite relationship between PM_{2.5}, neurodegenerative disease pathology, and cognitive and functional outcomes has not been studied.

To address this knowledge gap, we studied here the relationships between PM_{2.5} exposure, neuropathologic change, and cognitive and functional impairment in a large, well-characterized autopsy cohort. Using high spatial resolution estimates of PM_{2.5} obtained from a validated prediction model,²⁰ we determined whether PM_{2.5} exposure was associated with dementia severity measured by CDR-SB scores to assess cognitive and functional

performance in a well-characterized autopsy cohort. We further evaluated whether PM_{2.5} exposure was associated with differences in the burden of the most common dementia-related neuropathologies including Alzheimer's disease neuropathologic change (ADNC), Lewy body disease (LBD), limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC), and cerebrovascular disease.²¹ Finally, we evaluated whether the effect of PM_{2.5} on dementia severity was mediated by neuropathologic change.

Methods

Study design and participants

We obtained harmonized demographic, clinical, and neuropathology data for autopsy cases from the Integrated Neurodegenerative Disease (INDD) database at the Center for Neurodegeneration Disease Research (CNDP) at the University of Pennsylvania as previously described.²² Cases were recruited mainly through the Penn Alzheimer's Disease Research Center which focuses on dementia of the Alzheimer's type (as opposed to vascular or other dementias) and the Penn Parkinson's Disease and Movement Disorder Center which includes a research cohort focusing on cognitive dysfunction in the setting of LBD. Details on the study cohort are provided in the appendix p 3 and 5. In brief, we restricted our autopsy cases to individuals older than the age of 40 with common neuropathological forms of dementia from 1998 through 2022. We excluded cases with missing neuropathology, *APOE* ε4 allele status, and/or residential address data resulting in a cohort of 861 cases.

Demographic and clinical assessment

Self-reported sex, race, ethnicity, and years of education, and physician-reported brain weight and *APOE* ε4 allele status were extracted from the INDD database. Dementia severity was based on Clinical Dementia Rating-Sum of Boxes (CDR-SB) scores, used as a

continuous variable. Age at the last CDR-SB testing and the number of years between the last CDR-SB test and death were also obtained.

Neuropathological assessment

Using consensus criteria,²³⁻²⁶ ten neuropathologic summary scores were obtained, representing four proteinopathies (tau, β -amyloid, α -synuclein, and TDP-43) and three cerebrovascular lesions (infarcts, amyloid angiopathy, arteriolosclerosis) for each case as follows: Thal amyloid phase (A scores from 0 to 3 representing Thal amyloid phase 0, 1/2, 3, and 4/5), Braak stage (B scores from 0 to 3 representing Braak stage 0, I/II, III/IV, and V/VI), CERAD score (C scores from 0 to 3 representing absent, mild, moderate, and severe neocortical neuritic plaque burden), level of ADNC (from 0 to 3 representing not, low, intermediate, and high level),²⁴ absence/presence of LBD (0, no Lewy pathology or brainstem LBD or 1, amygdala-predominant, limbic/transitional, or neocortical/diffuse LBD),²³ LATE-NC stage (from 0 to 3),²⁵ absence/presence of large infarcts, absence/presence of moderate to high occipital cerebral amyloid angiopathy burden, absence/presence of moderate to high arteriolosclerosis in occipital white matter, and likelihood that cerebrovascular pathology contributed to cognitive impairment (VCING scores from 1 to 3 representing low, intermediate, and high likelihood).²⁶ Further details are described in appendix p 4..

Air pollution exposure assessment

Ambient PM_{2.5} exposure was estimated using annual average PM_{2.5} concentrations across the US at a 0.01°×0.01° (approximately 1.1km x 1.1km) grid cell resolution from 1998 to 2022, by combining satellite retrievals, chemical transport modelling and ground-based observations (V5.GL.04). These data were recently updated based on previously described data sets²⁰ and are publicly available through the Washington University, St. Louis. We then

spatially matched each case's geocoded residential addresses before death to grid cells to obtain one-year average PM_{2.5} exposures prior to death as a continuous variable (appendix p 4).

Statistical analysis

We used linear regression to estimate the cross-sectional association of one-year average PM_{2.5} concentrations prior to death with CDR-SB scores at last assessment prior to death, adjusting for sex, age at CDR-SB assessment, race, and years of education. For the subset of cases with multiple CDR-SB records, we used a linear mixed-effects model to estimate an adjusted association of PM_{2.5} concentrations with longitudinal change in CDR-SB scores.

Ordinal logistic regression models were used to estimate the association between PM_{2.5} concentration and ordered categorical outcomes that included Thal amyloid phase, Braak stage, CERAD score, ADNC level, LATE-NC stage, and VCING likelihood level. Binary logistic regression models were used to estimate the association between PM_{2.5} concentration and the presence/absence of LBD, large infarcts, occipital lobe cerebral amyloid angiopathy, and occipital white matter arteriolosclerosis. These models were adjusted for sex, age at death, and *APOE* ε4 allele status.

To explore the tripartite relationship between PM_{2.5} concentration, CDR-SB scores, and neuropathologic change as an ordered categorical mediator, we performed a mediation analysis with structural equation modelling using the R “lavaan” package.²⁷ PM_{2.5} exposure was the exogenous independent variable, ADNC and large infarcts were potential endogenous mediators, CDR-SB was the endogenous dependent variable, and sex, age at CDR assessment, interval years between CDR assessment and death, race, years of education, and *APOE* ε4 allele status were exogenous control variables. In this model, age at

death was not included as a control variable as it showed a perfect multicollinearity with a linear combination of age at CDR assessment and interval years between CDR assessment and death variables. We estimated indirect, direct, and total effects using a bias-corrected, accelerated bootstrap confidence interval method with 2000 simulations. Dichotomous nuisance variables were encoded as follows: sex (0, female, reference group; 1, male), race (0, non-white, reference group; 1, white), *APOE* ϵ 4 allele status (0, no *APOE* ϵ 4 (-), reference group; 1, *APOE* ϵ 4 (+)). Diagnostic tests were performed to assess model fitness (appendix p 4).

To explore the robustness of our findings, additional sensitivity analyses were performed using additional exposure time windows corresponding to 3-year and 5-year average PM_{2.5} exposure before their death. Analyses were performed with R version 4.2.3. All statistical tests were two-sided.

Results

Cohort characteristics

Demographic, clinical, and neuropathological features of the cohort are provided in table 1. Within the cohort, 481 (55.9%) were male, the mean (SD) age of death was 76.6 (10.3) years, most of the subjects were white (92.4%) and non-Hispanic or Latino (98.7%), and 49.4% carried at least one ϵ 4 allele of the *APOE* which is the strongest genetic risk factor for sporadic AD. Overall, our cohort was highly educated with an average of 15.3 years of education, with a moderate level of dementia corresponding to an average CDR-SB score of 10.0 at last assessment. Annual average change in CDR-SB scores was 1.6 with an average assessment interval of 5 years. The most common clinical diagnoses were AD (36.7%) and Parkinson's disease with dementia (15.7%).

More than a half of the cohort exhibited severe AD neuropathologic measures including Thal amyloid phase 4/5 (60.9%), Braak stage V/VI (52.5%), CERAD score 3 (54.9%), and high overall ADNC (50.6%). 53.1% exhibited LBD, and 30.1% exhibited LATE-NC. Notably, cerebrovascular disease was not a common feature of this autopsy cohort with relatively few cases exhibiting large infarcts (5.6%), moderate to severe occipital lobe cerebral amyloid angiopathy (27.3%), moderate to severe occipital white matter arteriolosclerosis burden (16.7%), or overall high likelihood that cerebrovascular pathology contributed to cognitive impairment (2.7%).

Air pollution and cognition

To determine whether this autopsy cohort was reasonably similar to epidemiologic observations that link PM_{2.5} exposure to impaired cognitive and functional performance, we spatiotemporally analyzed PM_{2.5} data for the study cohort based on geocoded addresses and the year of death ranging from 1998 to 2022 (appendix p 6 – 8). One-year average PM_{2.5} exposures before death was 10.1 µg/m³, ranging from 5 to 18.6 µg/m³. The average PM_{2.5} concentration decreased by 51.8% from 2000 through 2022, which was highly correlated with the 42.2% decrease in PM_{2.5} concentrations across the entire US over the same period (n=23, r = 0.97, and p < 0.001 by Spearman's rank correlation; appendix p 7 - 8).

Each 1 µg/m³ increase in one-year average exposure to PM_{2.5} before death was associated with a 0.78 point increase in the last CDR-SB score before death (95% confidence interval [CI], 0.52-1.05), indicating that more air pollution was associated with worse cognitive and functional impairment. This relationship appeared to be independent of the adjusted protective effect of education on cognitive and functional impairment, where each one-year increment in educational attainment was associated with a 0.31 point decrease in last CDR-SB score prior to death (95% CI, -0.53 - -0.09; table 2).

In addition, each 1 $\mu\text{g}/\text{m}^3$ increase in one-year average exposure to $\text{PM}_{2.5}$ before death was associated with a 0.13 point increase in annual change in CDR-SB scores (95% CI, 0.09-0.16; table 3), indicating that more air pollution was associated with faster cognitive and functional decline.

Air pollution and neuropathologic change

The adjusted relationship between $\text{PM}_{2.5}$ exposure and dementia-related neuropathologies was examined. Every 1 $\mu\text{g}/\text{m}^3$ increase in one-year average exposure to $\text{PM}_{2.5}$ before death was associated with overall an increased odds ratio for worse neuropathologic outcomes including higher Thal amyloid phase (odds ratio [OR], 1.07; 95% CI, 1.01-1.13), Braak stage (OR, 1.07; 95% CI, 1.02-1.13), CERAD score (OR, 1.11; 95% CI, 1.05-1.17), level of ADNC (OR, 1.06; 95% CI, 1.01-1.12), and prevalence of large infarcts (OR, 1.17; 95% CI, 1.05-1.30). In contrast, $\text{PM}_{2.5}$ was not associated with LBD stage (OR, 1.01; 95% CI, 0.96-1.06), LATE-NC stage (OR, 1.02; 95% CI, 0.96-1.08), prevalence of moderate or severe occipital lobe cerebral amyloid angiopathy burden (OR, 0.98; 95% CI, 0.92-1.04), occipital white matter arteriolosclerosis burden (OR, 0.99; 95% CI, 0.92-1.06), and overall VCING level (OR, 1.05; 95% CI, 0.97-1.14) (figure. 1).

Air pollution, neuropathologic change, and dementia

Based on the findings above that exposure to higher $\text{PM}_{2.5}$ levels was associated with increased CDR-SB scores (table 2), increased ADNC, and increased cerebrovascular disease (figure 1), we examined whether the association between $\text{PM}_{2.5}$ and CDR-SB was mediated by ADNC or the presence of large infarcts. A parallel mediation analysis with structural equation modelling revealed a significant mediation effect of ADNC (indirect effect; estimated change in CDR-SB scores due to increasing ADNC level, 0.36; 95% CI, 0.13-0.65)

on the association between PM_{2.5} exposure and CDR-SB scores, where about 63% of the estimated total effect of PM_{2.5} exposure on CDR-SB scores (estimated change in CDR-SB scores, 0.57; 95% CI, 0.35-0.81) was mediated via ADNC. The presence of large infarcts was not a statistically significant mediator (indirect effect; estimated change in CDR-SB scores due to increasing prevalence of large infarcts, 0.11; 95% CI, -0.11 - 0.87), and the estimated direct effect of PM_{2.5} on CDR-SB independent from ADNC and the presence of large infarcts was not significant (estimated change in CDR-SB scores independent from ADNC level and the presence of large infarcts, 0.10; 95% CI, -0.48 - 0.72). This adjusted model yielded adequate model fit indices (comparative fit index, 0.895; root mean square error of approximation, 0.088; Tucker-Lewis index, 0.965) (figure. 2).

Additional Sensitivity Analyses

Post hoc sensitivity analyses using expanded PM_{2.5} exposure time frames of either 3- or 5-years prior to death were largely similar to the results obtained from our primary analysis with the exception that 5-year average PM_{2.5} exposure before death was associated with a marginally decreased odds ratio for a higher prevalence of moderate or severe burden of occipital lobe cerebral amyloid angiopathy (appendix p 9 - 13).

Discussion

In this relatively large autopsy series, we found that exposure to higher PM_{2.5} levels was associated with significantly greater and faster cognitive and functional impairment. Higher PM_{2.5} concentrations were also associated with more severe amyloid and tau pathologies, culminating in more advanced overall ADNC. Higher PM_{2.5} exposure was also associated with a higher prevalence of large infarcts. Most importantly, the impact of PM_{2.5} on dementia severity was largely mediated by an increase in ADNC. These results suggest

that PM_{2.5} may directly affect brain vulnerability where increased ADNC appears to mediate PM_{2.5}-induced cognitive dysfunction. These associations were not modified by sex or *APOE* ε4 allele status.

Our findings are consistent with prior population-based cohort studies which have demonstrated cross-sectional associations between PM_{2.5} exposure and cognitive decline.^{3,11} Moreover, antemortem human studies consistently show that PM_{2.5} exposure is associated with increased AD biomarkers including structural MRI changes, cerebrospinal fluid measures,¹³ and amyloid PET outcomes.^{14,28-30} These support the hypothesis that PM_{2.5} exposure is deleterious for brain maintenance pathways, resulting in worsening of ADNC.^{31,32}

Two prior studies examining the effects of PM_{2.5} on neurodegenerative disease pathology have been reported, one of which demonstrated a similar association between higher PM_{2.5} exposure and higher ADNC (CERAD score) based on study of an Alzheimer's Disease Research Center autopsy cohort.¹⁹ In contrast, no significant effect of PM_{2.5} exposure and amyloid, tau or overall ADNC was observed in the second study of a community-based autopsy cohort.¹⁸ This inconsistency may be related to differences in autopsy cohort characteristics. Our cohort consisted mainly of symptomatic dementia cases that were enriched for AD dementia, perhaps allowing for more homogeneity and therefore statistical power to detect Alzheimer's disease specific effects and in contrast with community-based cohorts where the causes of cognitive dysfunction are likely to be more heterogeneous. In contrast with these prior studies, we included individual cases' cognitive and functional testing data which revealed that the relationship between PM_{2.5} exposure and cognitive and functional dysfunction was largely mediated by increased ADNC.

One strength of this study is the comprehensive study of a large autopsy series with well-defined demographical, clinical, and neuropathological profiles based on consensus criteria. Furthermore, we used high resolution prediction data to estimate individual-level

PM_{2.5} exposure at each residential location, and the air pollution exposure within this cohort was similar to overall trends in PM_{2.5} concentrations across the country. Finally, we demonstrated the robustness of our findings with sensitivity analyses demonstrating that similar results were obtained when using 1-, 3- or 5-years PM_{2.5} exposure before death.

Despite these strengths, we note the following limitations. First, the vast majority of subjects in our cohort were white and/or non-Hispanic or Latino, so our findings cannot be extrapolated to general population and are limited in terms of finding potential modifying effects of race and/or ethnicity. Second, due to the cross-sectional nature of autopsy studies, we were limited to fully examine longitudinal effects of air pollution on neuropathologic outcomes. Third, our autopsy cohort included a large proportion of cases through research programs that did not enroll individuals with vascular dementia. This selection bias resulted in very few cases in this cohort with severe cerebrovascular pathology, likely underestimating associations with PM_{2.5} of cerebrovascular disease. Indeed, there is strong epidemiologic evidence linking PM_{2.5} exposure and stroke.^{33,34} Finally, in this retrospective approach, we cannot comprehensively evaluate potential confounding factors, including differences in longitudinal exposures, that may affect downstream neuropathologic change and cognition.

Conclusions

This autopsy cohort study reinforces the finding that PM_{2.5} exposure appears to negatively affect cognitive function and suggests that this relationship may be mediated by ADNC. Our findings suggest that PM_{2.5} exposure may exacerbate AD pathogenesis. Thus, efforts to improve air quality may benefit the population by diminishing risk for Alzheimer's disease neuropathology.

Contributors

BK and EBL conceptualized and designed the study, did statistical analysis, and drafted the Article. All authors gathered and interpreted data, assisted with revisions, and approved the final version. EBL supervised the study.

Declaration of interests

EBL serves as a paid consultant to Wavebreak Therapeutics. DAW has served as a paid consultant to Eli Lilly, GE Healthcare, and Qynapse. DAW serves on a DSMB for Functional Neuromodulation and GSK. DAW receives research support paid to his institution from Biogen. TMP is founder of Penzymes, LLC; he is a consultant for Propella therapeutics and member of the Expert Panel for the Research Institute of Fragrance Materials. All other authors declare no competing interests.

Acknowledgments

This work was funded by the US National Institutes of Health (P30AG072979, P01AG066597, U19AG062418, P30ES013508). We thank the patients and their families for contributing to our research and for participating in the brain donation program. We are indebted to John Q. Trojanowski for his contributions which persist posthumously.

References

1. Wilker EH, Osman M, Weisskopf MG. Ambient air pollution and clinical dementia: systematic review and meta-analysis. *BMJ* 2023; **381**: e071620.
2. Shi L, Zhu Q, Wang Y, *et al.* Incident dementia and long-term exposure to constituents of fine particle air pollution: A national cohort study in the United States. *Proc Natl Acad Sci U S A* 2023; **120**: e2211282119.
3. Zare Sakhvidi MJ, Yang J, Lequy E, *et al.* Outdoor air pollution exposure and cognitive performance: findings from the enrolment phase of the CONSTANCES cohort. *Lancet Planet Health* 2022; **6**: e219-e29.
4. Weuve J, Bennett EE, Ranker L, *et al.* Exposure to Air Pollution in Relation to Risk of Dementia and Related Outcomes: An Updated Systematic Review of the Epidemiological Literature. *Environ Health Perspect* 2021; **129**: 96001.
5. Grande G, Wu J, Ljungman PLS, Stafoggia M, Bellander T, Rizzuto D. Long-Term Exposure to PM_{2.5} and Cognitive Decline: A Longitudinal Population-Based Study. *J Alzheimers Dis* 2021; **80**: 591-9.
6. Mintun MA, Lo AC, Duggan Evans C, *et al.* Donanemab in Early Alzheimer's Disease. *N Engl J Med* 2021; **384**: 1691-704.
7. van Dyck CH, Swanson CJ, Aisen P, *et al.* Lecanemab in Early Alzheimer's Disease. *N Engl J Med* 2023; **388**: 9-21.
8. Tsai TL, Lin YT, Hwang BF, *et al.* Fine particulate matter is a potential determinant of Alzheimer's disease: A systemic review and meta-analysis. *Environ Res* 2019; **177**: 108638.
9. Wood D, Evangelopoulos D, Beevers S, Kitwiroon N, Katsouyanni K. Exposure to Ambient Air Pollution and the Incidence of Dementia in the Elderly of England: The ELSA Cohort. *Int J Environ Res Public Health* 2022; **19**.

10. Chen JC, Wang X, Wellenius GA, *et al.* Ambient air pollution and neurotoxicity on brain structure: Evidence from women's health initiative memory study. *Ann Neurol* 2015; **78**: 466-76.
11. Cho J, Jang H, Park H, *et al.* Alzheimer's disease-like cortical atrophy mediates the effect of air pollution on global cognitive function. *Environment International* 2023; **171**: 107703.
12. Younan D, Petkus AJ, Widaman KF, *et al.* Particulate matter and episodic memory decline mediated by early neuroanatomic biomarkers of Alzheimer's disease. *Brain* 2020; **143**: 289-302.
13. Casey E, Li Z, Liang D, *et al.* Association between Fine Particulate Matter Exposure and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease among a Cognitively Healthy Population-Based Cohort. *Environ Health Perspect* 2024; **132**: 47001.
14. Iaccarino L, La Joie R, Lesman-Segev OH, *et al.* Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment. *JAMA Neurology* 2021; **78**: 197-207.
15. Yannatos I, Stites S, Brown RT, McMillan CT. Contributions of neighborhood social environment and air pollution exposure to Black-White disparities in epigenetic aging. *PLoS One* 2023; **18**: e0287112.
16. Fu P, Yung KKL. Air Pollution and Alzheimer's Disease: A Systematic Review and Meta-Analysis. *J Alzheimers Dis* 2020; **77**: 701-14.
17. You R, Ho Y-S, Chang RC-C. The pathogenic effects of particulate matter on neurodegeneration: a review. *Journal of Biomedical Science* 2022; **29**: 15.
18. Shaffer RM, Li G, Adar SD, *et al.* Fine Particulate Matter and Markers of Alzheimer's Disease Neuropathology at Autopsy in a Community-Based Cohort. *J Alzheimers Dis* 2021; **79**: 1761-73.

19. Christensen GM, Li Z, Liang D, *et al.* Association of PM_{2.5} Exposure and Alzheimer Disease Pathology in Brain Bank Donors-Effect Modification by APOE Genotype. *Neurology* 2024; **102**: e209162.
20. van Donkelaar A, Hammer MS, Bindle L, *et al.* Monthly Global Estimates of Fine Particulate Matter and Their Uncertainty. *Environmental Science & Technology* 2021; **55**: 15287-300.
21. Mehta RI, Schneider JA. Neuropathology of the Common Forms of Dementia. *Clin Geriatr Med* 2023; **39**: 91-107.
22. Toledo JB, Van Deerlin VM, Lee EB, *et al.* A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. *Alzheimers Dement* 2014; **10**: 477-84.e1.
23. McKeith IG, Boeve BF, Dickson DW, *et al.* Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. *Neurology* 2017; **89**: 88-100.
24. Montine TJ, Phelps CH, Beach TG, *et al.* National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. *Acta Neuropathol* 2012; **123**: 1-11.
25. Nelson PT, Dickson DW, Trojanowski JQ, *et al.* Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. *Brain* 2019; **142**: 1503-27.
26. Skrobot OA, Attems J, Esiri M, *et al.* Vascular cognitive impairment neuropathology guidelines (VCING): the contribution of cerebrovascular pathology to cognitive impairment. *Brain* 2016; **139**: 2957-69.
27. Rosseel Y. lavaan: An R Package for Structural Equation Modeling. *Journal of Statistical Software* 2012; **48**: 1 - 36.

28. Hajat A, Park C, Adam C, *et al.* Air pollution and plasma amyloid beta in a cohort of older adults: Evidence from the Ginkgo Evaluation of Memory study. *Environ Int* 2023; **172**: 107800.
29. Alemany S, Crous-Bou M, Vilor-Tejedor N, *et al.* Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. *Environment International* 2021; **157**: 106864.
30. Calderón-Garcidueñas L, Mukherjee PS, Waniek K, *et al.* Non-Phosphorylated Tau in Cerebrospinal Fluid is a Marker of Alzheimer's Disease Continuum in Young Urbanites Exposed to Air Pollution. *Journal of Alzheimer's Disease* 2018; **66**: 1437-51.
31. Clifford A, Lang L, Chen R, Anstey KJ, Seaton A. Exposure to air pollution and cognitive functioning across the life course--A systematic literature review. *Environ Res* 2016; **147**: 383-98.
32. Thiankhaw K, Chattipakorn N, Chattipakorn SC. PM2.5 exposure in association with AD-related neuropathology and cognitive outcomes. *Environ Pollut* 2022; **292**: 118320.
33. Bo Y, Zhu Y, Zhang X, *et al.* Spatiotemporal Trends of Stroke Burden Attributable to Ambient PM(2.5) in 204 Countries and Territories, 1990-2019: A Global Analysis. *Neurology* 2023; **101**: e764-e76.
34. Shah AS, Lee KK, McAllister DA, *et al.* Short term exposure to air pollution and stroke: systematic review and meta-analysis. *Bmj* 2015; **350**: h1295.




Figure 1. PM_{2.5} exposure and dementia-related neuropathologies.

Abbreviations: CERAD, Consortium to Establish a Registry for Alzheimer's Disease;

ADNC, Alzheimer's disease neuropathologic change; LBD, Lewy body disease; LATE,

limbic-predominant age-related TDP-43 encephalopathy; VCING, vascular cognitive

impairment neuropathology guidelines; CI, confidence interval.

Forest plot of odds ratios and 95% confidence intervals for neuropathologic outcomes

corresponding to every 1 $\mu\text{g}/\text{m}^3$ increase in one-year average PM_{2.5} exposure before death for

study cases. Odds ratios and 95% confidence intervals are reported from a series of ordinal

logistic regression models with one-year average PM_{2.5} before death as the exposure variable

and ordinal Thal amyloid phase, ordinal Braak stage, ordinal CERAD score, ordinal ADNC

level, ordinal LATE-NC stage, and ordinal VCING score as outcome variables, and binary

logistic regression models with one-year average PM_{2.5} exposure before death as the

exposure variable and dichotomously treated LBD stage, presence of large infarcts, presence

of occipital cerebral amyloid angiopathy, and presence of arteriolosclerosis as outcome

variables. The odds ratios and 95% confidence intervals greater than 1 indicate worse

neuropathologic outcomes. All models were controlled for sex, age at death, and *APOE* $\epsilon 4$

status. 861 cases with non-missing values were used for all analyses. P values less than 0.05 were considered statistically significant.




Figure 2. Alzheimer’s disease neuropathologic change mediates the relationship between PM_{2.5} exposure and Clinical Dementia Rating–Sum of Boxes (CDR-SB)

Abbreviations: ADNC, Alzheimer’s disease neuropathologic change; CI, confidence interval.

Panel A displays a path diagram of the structural equation modelling for relationships among PM_{2.5} exposure, ADNC or the presence of large infarcts, and CDR-SB with one-year average PM_{2.5} exposure before death as the exposure variable, ordinal ADNC level and presence of infarcts as parallel mediators, and CDR-SB at last assessment as the outcome variable. In this model, indirect effects are the effect of PM_{2.5} exposure on CDR-SB through ADNC (solid arrow, top) or the presence of large infarcts (solid arrow, bottom) and the direct effect is the effect of PM_{2.5} exposure on CDR-SB that is independent from mediators such as ADNC or presence of large infarcts (dotted arrow). Panel B shows estimates of indirect, direct, and total effects with 95% confidence intervals from mediation analysis based on structural equation

modelling using a bias-corrected and accelerated bootstrap confidence interval method with 2000 simulations. Positive values indicate greater cognitive and functional impairment. This model was controlled for sex, age at death, interval years between last CDR-SB assessment and death, race, years of education, and *APOE* ϵ 4 status as confounding variables. 348 cases with CDR-SB data were used for this analysis.

Table 1. Characteristics of study participants.

Characteristic	No. of Subjects	% or mean±SD
Demographic		
Sex	861	
Male	481	55.9
Female	380	44.1
Age at death - yr	861	76.6±10.3
Race ^a	847	
White	783	92.4
Non-White	64	7.6
Ethnicity ^a	764	
Not Hispanic or Latino	754	98.7
Hispanic or Latino	10	1.3
Brain weight - g	858	1211.6±171.8
<i>APOE</i> ε4 allele status	861	
<i>APOE</i> ε4 (+)	425	49.4
ε2/ε4	20	2.3
ε3/ε4	307	35.7
ε4/ε4	98	11.4
<i>APOE</i> ε4 (-)	436	50.6
ε2/ε2	3	0.3
ε2/ε3	64	7.4
ε3/ε3	369	42.9

Education - yr	616	15.3±3.1
Clinical		
CDR-SB at last assessment ^b	348	10±6.4
Age at last CDR-SB assessment -yr	348	76.1±10.7
Interval between last CDR-SB assessment and death -yr	348	2.9±3
Annual change in CDR-SB	263	1.6±1.9
Primary clinical diagnosis		
Possible/Probable Alzheimer's disease	316	36.7
Parkinson's disease with dementia	135	15.7
Neurologically normal	111	12.9
Parkinson's disease	72	8.4
Dementia with Lewy bodies	67	7.8
Frontotemporal degeneration	48	5.6
Corticobasal syndrome	33	3.8
Logopenic primary progressive aphasia	16	1.9
Mild cognitive impairment	13	1.5
Vascular dementia	12	1.4
Dementia, uncertain etiology	9	1
Posterior cortical atrophy	7	0.8
Other	22	2.6
Neuropathological ^c		
Thal amyloid phase	861	
0	82	9.5
1/2	126	14.6

3	129	15.0
4/5	524	60.9
Braak NFT stage	861	
0	34	3.9
I/II	225	26.1
III/IV	150	17.4
V/VI	452	52.5
CERAD score	861	
0	197	22.9
1	69	8.0
2	122	14.2
3	473	54.9
ADNC level	861	
Not	81	9.4
Low	214	24.9
Intermediate	130	15.1
High	436	50.6
Lewy pathology	861	
No or brainstem predominant	404	46.9
Amygdala, transitional/limbic, of diffuse/neocortical predominant	457	53.1
LATE	861	
No	602	69.9
LATE-NC stage 1	54	6.3
LATE-NC stage 2	176	20.4

LATE-NC stage 3	29	3.4
Large infarct	861	
No	813	94.4
Yes	48	5.6
Cerebral amyloid angiopathy burden in occipital lobe	861	
Absent to mild	626	72.7
Moderate to severe	235	27.3
Arteriolosclerosis burden in occipital white matter	861	
Absent to mild	717	83.3
Moderate to severe	144	16.7
VCING level	861	
Low	770	89.4
Intermediate	68	7.9
High	23	2.7

Abbreviations: NFT, neurofibrillary tangle; CERAD, Consortium to Establish a Registry for Alzheimer's Disease; ADNC, Alzheimer's disease neuropathologic change; LATE, limbic-predominant age-related TDP-43 encephalopathy; VCING, vascular cognitive impairment neuropathology guidelines.

^a Race and ethnicity were reported by the study subjects.

^b Scores on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) at last assessment prior to death range from 0 to 18, with higher scores indicating greater cognitive and functional impairment.

^c All pathological measures were recorded according to consensus criteria.

Table 2. PM_{2.5} exposure and Clinical Dementia Rating–Sum of Boxes (CDR-SB).^a

Exposure	Estimate (95% CI) ^b	P Value ^c
No. of participants (N)=348 ^d		
PM _{2.5}	0.78 (0.52 - 1.05)	<0.001
Education	-0.31 (-0.53 - -0.09)	0.005

Abbreviation: CI, confidence interval.

^a Associations were evaluated by a linear regression model in which the outcome variable was Clinical Dementia Rating-Sum of Boxes (CDR-SB) score at last assessment with higher values indicating greater cognitive and functional impairment, the exposure variables were one-year average PM_{2.5} exposure before death and years of education, and covariates were sex, age at last CDR-SB assessment, and race.

^b Estimated effects and 95% confidence intervals were shown adjusted changes in scores on CDR-SB at last assessment prior to death per 1 µg/m³ increase in one-year average PM_{2.5} exposure before death and one-year increase in educational attainment, with positive values indicating greater cognitive and functional impairment.

^c P values less than 0.05 were considered statistically significant.

^d 348 cases with CDR-SB data were included in this analysis.

Table 3. PM_{2.5} exposure and longitudinal change in Clinical Dementia Rating–Sum of Boxes (CDR-SB).^a

Exposure	Estimate (95% CI) ^b	P Value ^c
No. of participants=236 ^d		
Interaction term between PM _{2.5} and interval years between CDR-SB assessment and death	0.13 (0.09, 0.16)	<0.001

Abbreviation: CI, confidence interval.

^a The association was evaluated by a linear mixed-effects model in which the outcome variable was annual change in Clinical Dementia Rating–Sum of Boxes (CDR-SB) scores obtained from multiple assessments with higher values indicating faster cognitive and functional impairment, the exposure variable was the interaction term between one-year average PM_{2.5} level exposed to study participants before their death and interval years between last CDR-SB assessment and death, and fixed covariates were interval years between last CDR-SB assessment and death, sex, age at last CDR-SB assessment, race, and years of education.

^b The estimated effect and 95% confidence interval were shown an adjusted annual change in scores on CDR-SB at last assessment prior to death per 1 µg/m³ increase in one-year average PM_{2.5} exposure before death, with positive values indicating faster cognitive and functional impairment.

^c P value less than 0.05 was considered statistically significant.

^d 236 cases with multiple CDR-SB data were included in this analysis.